» Articles » PMID: 27564778

Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures

Overview
Specialty Rheumatology
Date 2016 Aug 27
PMID 27564778
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Electronic clinical quality measures (eCQMs) rely on computer algorithms to extract data from electronic health records (EHRs). On behalf of the American College of Rheumatology (ACR), we sought to develop and test eCQMs for rheumatoid arthritis (RA).

Methods: Drawing from published ACR guidelines, a working group developed candidate RA process measures and subsequently assessed face validity through an interdisciplinary panel of health care stakeholders. A public comment period followed. Measures that passed these levels of review were electronically specified using the quality data model, which provides standard nomenclature for data elements (category, datatype, and value sets) obtained through an EHR. For each eCQM, 3 clinical sites using different EHR systems tested the scientific feasibility and validity of measures. Measures appropriate for accountability were presented for national endorsement.

Results: Expert panel validity ratings were high for all measures (median 8-9 of 9). Health system performance on the eCQMs was 53.6% for RA disease activity assessment, 69.1% for functional status assessment, 93.1% for disease-modifying antirheumatic drug (DMARD) use, and 72.8% for tuberculosis screening. Kappa statistics, which evaluated whether the eCQM validly captured data obtained from manual EHR chart review, demonstrated moderate to substantial agreement (0.54 for functional status assessment, 0.73 for tuberculosis screening, 0.84 for disease activity, and 0.85 for DMARD use).

Conclusion: Four eCQMs for RA have achieved national endorsement and are recommended for use in federal quality reporting programs. Implementation and further refinement of these measures is ongoing in the ACR's registry, the Rheumatology Informatics System for Effectiveness (RISE).

Citing Articles

Cannabinoid receptor 2 selective agonist ameliorates adjuvant-induced arthritis by modulating the balance between Treg and Th17 cells.

Tian N, Yang C, Du Y, Chen M, Li B, Li D Front Pharmacol. 2025; 16:1532518.

PMID: 39959429 PMC: 11825454. DOI: 10.3389/fphar.2025.1532518.


Patient perceptions of an electronic-health-record-based rheumatoid arthritis outcomes dashboard: a mixed-methods study.

Nasrallah C, Wilson C, Hamblin A, Hariz C, Young C, Li J BMC Med Inform Decis Mak. 2024; 24(1):302.

PMID: 39395970 PMC: 11470722. DOI: 10.1186/s12911-024-02696-9.


Using the technology acceptance model to assess clinician perceptions and experiences with a rheumatoid arthritis outcomes dashboard: qualitative study.

Nasrallah C, Wilson C, Hamblin A, Young C, Jacobsohn L, Nakamura M BMC Med Inform Decis Mak. 2024; 24(1):140.

PMID: 38802865 PMC: 11129391. DOI: 10.1186/s12911-024-02530-2.


Development of the American College of Rheumatology Patient-Reported Outcome Quality Measures for Systemic Lupus Erythematosus.

Katz P, Barber C, Duarte-Garcia A, Garg S, Machua W, Rodgers W Arthritis Care Res (Hoboken). 2024; 76(6):777-787.

PMID: 38225171 PMC: 11132939. DOI: 10.1002/acr.25301.


[Neutrophil-lymphocyte and platelet-lymphocyte ratios for assessing disease activity in patients with rheumatoid arthritis receiving tofacitinib treatment].

Tang J, Chen J, Lin G, Zhang H, Gui M, Li N Nan Fang Yi Ke Da Xue Xue Bao. 2023; 43(10):1651-1656.

PMID: 37933639 PMC: 10630215. DOI: 10.12122/j.issn.1673-4254.2023.10.01.


References
1.
Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

2.
Alemao E, Joo S, Kawabata H, Al M, Allison P, Molken M . Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care Res (Hoboken). 2015; 68(3):308-17. PMC: 5067571. DOI: 10.1002/acr.22678. View

3.
Anderson J, Caplan L, Yazdany J, Robbins M, Neogi T, Michaud K . Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012; 64(5):640-7. PMC: 4028066. DOI: 10.1002/acr.21649. View

4.
Pincus T, Castrejon I . MDHAQ/RAPID3 scores: quantitative patient history data in a standardized "scientific" format for optimal assessment of patient status and quality of care in rheumatic diseases. Bull NYU Hosp Jt Dis. 2011; 69(3):201-14. View

5.
Maclean C, Saag K, Solomon D, Morton S, Sampsel S, Klippel J . Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum. 2004; 51(2):193-202. DOI: 10.1002/art.20248. View